In the prophylactic treatment of patients with hemophilia A, particularly its severe form, concentrates of clotting factor VIII (FVIII) with extended half-life (EHL) are increasingly administered, or non-factor treatment, represented in clinical practice by FVIII mimetic antibody emicizumab. However, insights into the direct comparison of effectiveness and economic burden arising from prophylaxis with these modalities are limited, including data from real-world practice. One recently published study therefore attempted to conduct such a…
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
